A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

• ClinicalTrials.gov Identifier: NCT02349451
• Recruitment Status: Completed
• First Posted: January 28, 2015
• Results First Posted: August 4, 2017
• Last Update Posted: August 4, 2017
• Sponsor: AbbVie
• Information provided by (Responsible Party): AbbVie

Study Description

Brief Summary:

This study is a Phase 2 randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT-122 in participants with active PsA who are inadequately responding to MTX treatment.

Condition or disease	Intervention/treatment	Phase
Psoriatic Arthritis	Biological: adalimumab; Biological: ABT-122	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 240 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate
• Actual Study Start Date: April 28, 2015
• Actual Primary Completion Date: July 4, 2016
• Actual Study Completion Date: July 4, 2016

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Adalimumab; Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks	Biological: adalimumab; Other Names: Humira; ABT-D2E7
Placebo Comparator: Placebo; Double-blind placebo administered every week (EW) for 12 weeks	Biological: ABT-122; Other Name: remtolumab
Experimental: ABT-122 120 mg; Double-blind ABT-122 120 mg administered EW for 12 weeks	Biological: ABT-122; Other Name: remtolumab
Experimental: ABT-122 240 mg; Double-blind ABT-122 240 mg administered EW for 12 weeks	Biological: ABT-122; Other Name: remtolumab

Outcome Measures

Primary Outcome Measures :

1. American College of Rheumatology (ACR) 20 Response Rate at Week 12: ABT-122 Versus Placebo [ Time Frame: Week 12 ]
   Percentage of participants with an ACR20 response, defined as at least 20% improvement (compared to baseline values) in tender and swollen joint counts and at least 20% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function and acute phase reactant high sensitivity C-reactive protein [hsCRP]). Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agresti-Coull method.

Secondary Outcome Measures :

1. ACR20 Response Rate at Week 12: ABT-122 Versus Adalimumab [ Time Frame: Week 12 ]
   Percentage of participants with an ACR20 response, defined as at least 20% improvement (compared to baseline values) in tender and swollen joint counts and at least 20% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function and acute phase reactant hsCRP). Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agresti-Coull method.
2. ACR50 Response Rate at Week 12 [ Time Frame: Week 12 ]
   Percentage of participants with an ACR50 response, defined as at least 50% improvement (compared to baseline values) in tender and swollen joint counts and at least 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function and acute phase reactant hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agresti-Coull method.
3. ACR70 Response Rate at Week 12 [ Time Frame: Week 12 ]
   Percentage of participants with an ACR70 response, defined as at least 70% improvement (compared to baseline values) in tender and swollen joint counts and at least 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function and acute phase reactant hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agresti-Coull method.
4. ACRn at Week 12 [ Time Frame: At Week 12 ]
   ACR measures percentage improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. ACRn is a continuous variable based on the ACR criteria. Improvement from baseline in a component of the ACR composite variable was computed as the difference between the baseline value and the value at a given post-baseline visit. A positive value for improvement from baseline for an individual component indicates lesser severity of disease. The 95% confidence interval for mean is constructed using T-statistic with significance level alpha=5%.
5. Change From Baseline in Disease Activity Score 28 (DAS28[hsCRP]) at Week 12 [ Time Frame: Baseline, Week 12 ]
   The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity.
6. Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Week 12 [ Time Frame: Baseline, Week 12 ]
   PASDAS is a continuous compound disease activity state score determined by the combined values of tender or swollen joint counts, participant-reported outcome and hsCRP lab test. The PASDAS is unitless, with a typical score range between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement.
7. Change From Baseline in Psoriasis Target Lesion Score at Week 12 [ Time Frame: Baseline, Week 12 ]
   Target lesion score for psoriasis in participants with psoriatic arthritis is calculated by adding the scores of plaque erythema, scaling and thickness. Scores range from 0 (no erythema or evidence of plaque thickness) to 10 (severe erythema and evidence of plaque thickness).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• PsA diagnosis of at least 3 months duration prior to the date of first screening with ClASsification of Psoriatic ARthritis (CASPAR) confirmed diagnosis at Screening.
• Have active psoriasis defined by at least 1 psoriasis lesion >= 2 cm diameter in areas other than the axilla or groin.

• Have active arthritis defined by minimum disease activity criteria:

  1. >= 3 swollen joints (based on 66 joint counts) at Screening
  2. >= 3 tender joints (based on 68 joint counts) at Screening

• On a stable dose of methotrexate (MTX) defined as:

  1. Oral or parenteral treatment >= 3 months
  2. On a stable dose with an unchanged mode of application for at least 4 weeks prior to baseline
  3. Stable MTX dose of >= 10 mg/week and <= the upper limit of the applicable approved local label
  4. Can also be on stable doses of nonsteroidal anti-inflammatory drugs, sulfasalazine and/or hydroxychloroquine as long as they are also on methotrexate

Exclusion Criteria:

• Up to 30% (approximately 66 subjects) with prior exposure to a TNF inhibitor may be enrolled if the TNF inhibitor was not discontinued due to lack of efficacy or safety concerns. Subjects must be washed out for at least 5 half-lives of these drugs prior to the Baseline visit.
• Subjects on prior adalimumab may not be enrolled in the study
• Prior exposure to other non-TNF inhibitor biological disease-modifying antirheumatic drugs (DMARDs) will be permitted if the subject is washed out at least 5 half-lives of these drugs prior to the baseline visit.

• Current treatment with traditional oral/intramuscular DMARDs, including conventional synthetic DMARDs (csDMARDs; except for concomitant treatment with sulfasalazine and/or hydroxychloroquine in addition to MTX). Oral DMARDs must be washed out for at least 5 half-lives of a drug apart from MTX prior to the Baseline visit.

  a. Subject could have been exposed to prior Janus kinase (JAK) or phosphodiesterase type 4 (PDE4) inhibitors so long as they have been off therapy for at least 5 half-lives.

• Stable prescribed dose of oral prednisone or prednisone equivalent > 10 mg/day within the 30 days of the Baseline visit.
• Intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks of the Baseline visit. Inhaled corticosteroids for stable medical conditions are allowed.

• Laboratory values of the following at the Screening Visit:

  1. Confirmed hemoglobin < 9 g/dL for males and < 8.5 g/dL for females
  2. Absolute neutrophil count (ANC) < 1500 mm^3, (or < 1200 cells/µL for subjects of African descent who are black)
  3. Aspartate aminotransferase or alanine aminotransferase > 1.5 x the upper limit of normal (ULN) or bilirubin >= 3 mg/dL
  4. Serum creatinine > 1.5 x the ULN
  5. Platelets < 100,000 cells/[mm^3] (10^9/L),
  6. Clinically significant abnormal screening laboratory results as evaluated by the Investigator

Contacts and Locations

Sponsors and Collaborators

AbbVie

Investigators

• Study Director: Paul Peloso, MD; AbbVie

More Information

Additional Information:

Humira Prescribing info 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Khatri A, Klünder B, Peloso PM, Othman AA. Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):352-360. doi: 10.1093/rheumatology/key312.

Mease PJ, Genovese MC, Weinblatt ME, Peloso PM, Chen K, Othman AA, Li Y, Mansikka HT, Khatri A, Wishart N, Liu J. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2018 Nov;70(11):1778-1789. doi: 10.1002/art.40579.

• Responsible Party: AbbVie
• ClinicalTrials.gov Identifier: NCT02349451
• Other Study ID Numbers: M14-197; 2014-003558-15 ( EudraCT Number )
• First Posted: January 28, 2015
• Results First Posted: August 4, 2017
• Last Update Posted: August 4, 2017
• Last Verified: August 2017

Keywords provided by AbbVie:

Safety; Efficacy; Methotrexate

Additional relevant MeSH terms:

Arthritis; Arthritis, Psoriatic; Joint Diseases; Musculoskeletal Diseases; Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Adalimumab; Anti-Inflammatory Agents; Antirheumatic Agents